Abstract
Multiple monoclonal antibodies have been shown to be effective for both prophylaxis and therapy for SARS-CoV-2 infection. Here we aggregate data from randomized controlled trials assessing the use of monoclonal antibodies in preventing symptomatic SARS-CoV-2 infection. We use data on changes in the in vivo concentration of monoclonal antibodies, and the associated protection from COVID-19, over time to model the dose-response relationship of monoclonal antibodies for prophylaxis. We estimate that 50% protection from COVID-19 is achieved with a monoclonal antibody concentration of 54-fold of the in vitro IC50 (95% CI: 16 – 183). This relationship provides a quantitative tool allowing prediction of the prophylactic efficacy and duration of protection for new monoclonal antibodies administered at different doses and against different SARS-CoV-2 variants.
Finally, we compare the relationship between neutralization titer and protection from COVID-19 after either monoclonal antibody treatment or vaccination. We find no evidence for a difference between the 50% protective titer for monoclonal antibodies and vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by an Australian government Medical Research Future Fund awards GNT2002073 (to MPD, SJK), MRF2005544 (to SJK and MPD), MRF2005760 (to MPD), an NHMRC program grant GNT1149990 (SJK and MPD), and the Victorian Government (SJK). DSK and SJK are supported by NHMRC fellowships. DC, ZKM and EMW and MPD are supported by NHMRC Investigator grants. KLC is supported by PhD scholarship from the Leukaemia Foundation, the Haematology Society of Australia and New Zealand (HSANZ) and Monash University. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involves the meta-analysis of human data that was all openly available prior to the commencement of the study. We searched MEDLINE, PubMed, Embase and the Cochrane COVID Study Register for randomized control trials of monoclonal antibodies for the prevention of COVID-19. We identified six studies. We included only the five studies where monoclonal antibody concentration as well as clinical outcomes were reported for the same cohort. Data was extracted from all eligible studies and which are listed below: 1.Isa, F., et al. Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19. Int J Infect Dis 122, 585-592 (2022). 2.Levin, M.J., et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med 386, 2188-2200 (2022). 3.O'Brien, M.P., et al. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. N Engl J Med 385, 1184-1195 (2021). 4.Herman, G.A., et al. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial. The Lancet Infectious Diseases (2022). 5.Schmidt, P., et al. Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. medRxiv, 2022.2010.2018.22281172 (2022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The meta-analysis now includes an additional mAb randomised control trial for the antibody Adintrevimab. All analysis, figures, text and supplementary materials have been updated accordingly.
Data Availability
All data was extracted from publicly available sources and all extracted data and code will be made available on GitHub upon publication.
